Jean‐Luc Canon

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

Jean‐Yves Douillard, Salvatore Siena, James T. Cassidy et al. · Journal of Clinical Oncology · 2010 · 1.8K citations

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer

Johan Vansteenkiste, Jean‐Luc Canon, Filippo de Braud et al. · Journal of Thoracic Oncology · 2015 · 158 citations · Full text

Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation

David Miles, David Cameron, Igor Bondarenko et al. · European Journal of Cancer · 2016 · 121 citations

First-line Therapy, Breast Oncology, Prospective Biomarker Evaluation +8

Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer

Eric Van Cutsem, Manuel Hidalgo, Jean‐Luc Canon et al. · International Journal of Cancer · 2018 · 100 citations · Full text

Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases?

Catherine Hubert, Christine Sempoux, Yves Horsmans et al. · Liver International · 2007 · 74 citations